Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro Protamine Suspension, Insulin Levemir; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more

Conditions: Bioequivalence in Healthy Subjects
Interventions: Insulin Lispro; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Diabetes Mellitus
Interventions: insulin glargine, insulin glulisine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Lispro Injection, Humalog; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anaheim, California • Fresno, California • Los Angeles, California + 52 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20); Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus
Interventions: MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200); Drug · Device
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Type1 Diabetes Mellitus
Interventions: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care; Device · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Jacksonville, Florida

Conditions: Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions: Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: Insulin glulisine, insulin lispro, insulin glargine, NPH insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: SAR342434, Humalog, insulin glargine HOE901; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 51
States / cities: Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection; Drug · Device
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes
Interventions: Lispro mix 75/25, Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus
Interventions: Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Concord, California • Encino, California • Escondido, California + 35 more

Conditions: Diabetes Mellitus Type 1
Interventions: Insulin LISPRO, recombinant human insulin; Drug
Lead sponsor: Biodel; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type II
Interventions: Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Concord, California • Encino, California • Escondido, California + 18 more

Conditions: Type 2 Diabetes Mellitus
Interventions: insulin lispro injection [rDNA origin] Low Mix; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 39
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 35 more

Conditions: Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions: Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 24
States / cities: Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more

Conditions: Healthy
Interventions: Recombinant human hyaluronidase PH20 (rHuPH20), Insulin lispro, Insulin glulisine, Insulin aspart; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Peglispro, Insulin Glargine, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Canakinumab 150 mg, Placebo to Canakinumab; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 11
States / cities: Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2605541, Insulin Glargine, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Healthy Volunteers
Interventions: rHuPH20, Insulin Human Injection, Insulin Lispro Injection; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects

Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy

The Insulin-Only Bionic Pancreas Bridging Study

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Afrezza® INHALE-1 Study in Pediatrics

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

A Study in Participants With Type 2 Diabetes Mellitus

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20